| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
1,250,000,000 |
| Market
Cap: |
80.88(B) |
| Last
Volume: |
7,412,694 |
Avg
Vol: |
8,704,124 |
| 52
Week Range: |
$63.43 - $87.29 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 500 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 259 |
| Guru Rank Value : 4.6 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Co.'s primary areas of focus include viral diseases, inflammatory diseases and oncology. Co.'s products include: Biktarvy® for the treatment of HIV-1 infection in certain patients; Veklury® (remdesivir), for the treatment of Coronavirus Disease 2019 requiring hospitalization; Epclusa® for the treatment of chronic hepatitis C virus infection; Vemlidy® for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease; Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
2,000 |
25,472 |
38,458 |
80,792 |
| Total Sell Value |
$145,920 |
$2,022,270 |
$3,052,046 |
$6,445,296 |
| Total People Sold |
1 |
3 |
3 |
4 |
| Total Sell Transactions |
1 |
5 |
9 |
14 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Young Kevin |
Chief Operating Officer |
• • – |
2017-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
620 |
2,190 |
|
- |
|
| Martin John C |
Executive Chairman |
• • – |
2017-01-03 |
4 |
AS |
$73.04 |
$5,396,971 |
D/D |
(73,337) |
3,131,096 |
|
- |
|
| Martin John C |
Executive Chairman |
• • – |
2017-01-03 |
4 |
OE |
$21.58 |
$1,582,246 |
D/D |
73,337 |
3,204,433 |
|
- |
|
| Wilson Gayle E |
Director |
• • – |
2016-12-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,147 |
107,486 |
|
- |
|
| Martin John C |
Executive Chairman |
• • – |
2016-12-01 |
4 |
AS |
$73.33 |
$7,332,870 |
D/D |
(100,000) |
3,131,096 |
|
- |
|
| Martin John C |
Executive Chairman |
• • – |
2016-12-01 |
4 |
OE |
$16.40 |
$1,639,500 |
D/D |
100,000 |
3,231,096 |
|
- |
|
| Bischofberger Norbert W |
EVP, R&D and CSO |
• • – |
2016-11-22 |
4 |
GD |
$0.00 |
$0 |
I/I |
10,000 |
2,306,849 |
|
- |
|
| Moore Nicholas G |
Director |
• • – |
2016-11-21 |
4 |
GD |
$0.00 |
$0 |
D/D |
3,406 |
11,882 |
|
- |
|
| Madigan John W |
Director |
• • – |
2016-11-18 |
4 |
S |
$74.86 |
$7,860,058 |
D/D |
(105,000) |
16,761 |
|
- |
|
| Madigan John W |
Director |
• • – |
2016-11-18 |
4 |
OE |
$20.71 |
$2,174,025 |
D/D |
105,000 |
121,761 |
|
- |
|
| Meyers James R |
EVP Worldwide Commercial OpsOf |
• – – |
2016-11-10 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
121,151 |
|
- |
|
| Meyers James R |
EVP Worldwide Commercial OpsOf |
• – – |
2016-11-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,726 |
|
- |
|
| Alton Gregg H |
EVP Comm&Acs ALA, Corp&Med Aff |
• • – |
2016-11-09 |
4 |
AS |
$79.00 |
$790,000 |
D/D |
(10,000) |
122,964 |
|
- |
|
| Martin John C |
Executive Chairman |
• • – |
2016-11-01 |
4 |
AS |
$73.73 |
$7,376,046 |
D/D |
(100,000) |
3,131,096 |
|
- |
|
| Martin John C |
Executive Chairman |
• • – |
2016-11-01 |
4 |
OE |
$16.40 |
$1,639,500 |
D/D |
100,000 |
3,231,096 |
|
- |
|
| Martin John C |
Executive Chairman |
• • – |
2016-10-03 |
4 |
AS |
$77.62 |
$7,762,961 |
D/D |
(100,000) |
3,131,096 |
|
- |
|
| Martin John C |
Executive Chairman |
• • – |
2016-10-03 |
4 |
OE |
$16.40 |
$1,639,500 |
D/D |
100,000 |
3,231,096 |
|
- |
|
| Alton Gregg H |
EVP Comm&Acs ALA, Corp&Med Aff |
• • – |
2016-09-22 |
4 |
AS |
$81.84 |
$409,220 |
D/D |
(5,000) |
132,964 |
|
- |
|
| Milligan John F |
President and CEO |
• • – |
2016-09-06 |
4 |
AS |
$77.74 |
$5,442,080 |
D/D |
(70,000) |
1,058,963 |
|
- |
|
| Milligan John F |
President and CEO |
• • – |
2016-09-06 |
4 |
OE |
$20.74 |
$1,451,800 |
D/D |
70,000 |
1,128,963 |
|
- |
|
| Martin John C |
Executive Chairman |
• • – |
2016-09-01 |
4 |
S |
$77.45 |
$7,748,363 |
D/D |
(100,000) |
3,131,096 |
|
- |
|
| Martin John C |
Executive Chairman |
• • – |
2016-09-01 |
4 |
OE |
$16.40 |
$1,639,500 |
D/D |
100,000 |
3,231,096 |
|
- |
|
| Martin John C |
Executive Chairman |
• • – |
2016-08-30 |
4 |
GD |
$0.00 |
$0 |
D/D |
156,714 |
3,131,096 |
|
- |
|
| Washington Robin L |
EVP, CFO |
• • – |
2016-08-29 |
4 |
GD |
$0.00 |
$0 |
I/I |
3,225 |
109,743 |
|
- |
|
| Bischofberger Norbert W |
EVP, R&D and CSO |
• • – |
2016-08-24 |
4 |
GD |
$0.00 |
$0 |
I/I |
2,800 |
2,316,849 |
|
- |
|
2499 Records found
|
|
Page 27 of 100 |
|
|
0.85 (1.33%) 
